Effectiveness of recently-approved oral antiviral medications on the outcome of patients with mild-to-moderate COVID-19 and preexisting chronic obstructive pulmonary diseases

CONCLUSIONS: This study revealed that oral antivirals - NMV-r or MOV might improve clinical outcomes in patients with preexisting COPD and COVID-19. However, only a small proportion of preexisting COPD patients with COVID-19 received oral antiviral treatment.PMID:38702925 | DOI:10.1080/14787210.2024.2351571

Source: Expert Review of Anti-Infective Therapy - May 4, 2024 Category: Infectious Diseases Authors: Bo-Wen Shiau Wan-Hsuan Hsu Ya-Wen Tsai Jheng-Yan Wu Ting-Hui Liu Po-Yu Huang Min-Hsiang Chuang Chih-Cheng Lai Lih-Wen Jang Source Type: research